Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis

Journal of Rheumatology

Volumn 30, Issue 6, 2003, Pages 1248-1252

  Khanna, Dhanita ^b   Aggarwal, Amita ^b   Bhakuni, Darshan S ^b   Dayal, Rajeshwar ^b   Misra, Ramnath ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b NONE

Author keywords

Autoantibodies; Connective Tissue Disease; Scleroderma

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CATHEPSIN G; ELASTASE; LACTOFERRIN; LYSOZYME; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY SCREENING; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SKIN; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CATHEPSINS; EPITOPES; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEROXIDASE; SCLERODERMA, SYSTEMIC; SERINE ENDOPEPTIDASES; SEROEPIDEMIOLOGIC STUDIES;

EID: 0037643312     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38:184-9.
2. Mayet WJ, Meyer zum Buschenfelde KH. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993;94:440-6.
3. Rastaldi MP, Ferrario F, Tunesi S, Yang L, D'Amico G. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. Am J Kidney Dis 1996;27:48-57.
4. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997;126:866-73.
5. Gross WL, Schmitt WH, Csernok E. Antineutrophil cytoplasmic autoantibody-associated diseases: a rheumatologist's perspective. Am J Kidney Dis 1991;18:175-9.
6. Akimoto S, Ishiwaka O, Tamura T, Miyachi Y. Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Br J Dermatol 1996;134:407-10.
7. Locke IC, Worrall JG, Leaker B, Black CM, Cambridge G. Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 1997;24:86-9.
8. Katrib A, Sturgess A, Bertouch JV. Systemic sclerosis and antineutrophil cytoplasmic autoantibody-associated renal failure. Rheumatol Int 1999;19:61-3.
9. Endo H, Hosono T, Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 1994;21:864-70.
10. Omote A, Muramatsu M, Sugimoto Y, et al. Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies-related scleroderma renal crisis treated with double filtration plasmapheresis. Intern Med 1997;36:508-13.
11. Carvajal I, Bernis C, Sanz P, Gracia A, Gracia-Vadillo A, Traver JA. Anti-neutrophil cytoplasmic autoantibodies and systemic sclerosis. Nephrol Dial Transplant 1997;12:576-7.
12. Masi AT, Rodnan GP, Medsger TA Jr, et al. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
13. Roberts DE, Rubin RL. Anti-neutrophil cytoplasmic autoantibodies. In: Rose NR, Conway de Macario E, Fahey J, Friedman H, Penn GM, editors. Manual of clinical laboratory immunology. Washington, DC: American Society for Microbiology; 1992:781-4.
14. Hillis GS, Khan IH, Simpson JG, Rees AJ. Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive anti-myeloperoxidase antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1997;30:279-81.
15. Vazquez-del Mercado M, Mendoza-Topete A, Best-Aguilera CR, Gracia-de la Torre I. Diffuse alveolar hemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies. J Rheumatol 1996; 23:1821-3.
16. Kumar A, Malaviya AN, Tiwari SC, Singh RR, Kumar A, Pande JN. Clinical and laboratory profile of systemic sclerosis in northern India. J Assoc Physicians India 1990;38:765-8.
17. Weiss J, Olsson I. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 1987;69:652-9.
18. Weiss J, Elsbach P, Olsson I, Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978;253:2664-72.
19. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein is an important antigen for anti-neutrophilic cytoplasmic autoantibodies in vasculitis. Clin Exp Immunol 1995;99:49-56.
20. Cooper T, Savige J, Nassis L, et al. Clinical associations and characterization of antineutrophilic antibodies directed against bactericidal/permeability-increasing protein and azurocidin. Rheumatol Int 2000;19:129-36.
21. Schultz H, Csemok E, Nikkari S, Toivanen P, Toivanen A, Gross WL. BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognize the C-terminal part of the BPI molecule. Scand J Rheumatol 2000;29:226-31.
22. Haapamaki MM, Haggblom JO, Gronroos JM, Pekkala E, Alanen K, Nevalainen TJ. Bactericidal/permeability-increasing protein in colonic mucosa in ulcerative colitis. Hepatogastroenterology 1999;46:2273-7.
23. Schultz H, Csernok E, Schuster A, Schmitz TS, Emst M, Gross WL. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI. Pediatr Allergy Immunol 2000;11:64-70.
24. Lindgren S, Nilsson S, Nassberger L, Verbaan H, Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver disease: prevalence, antigen specificity and predictive value for the diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J Gastroenterol Hepatol 2000; 15:437-42.
25. Chiappini E, Taccetti G, Campana S, Turchini S, Marianelli L. Anti-pseudomonas aeruginosa antibodies, circulating immune complexes and anticytoplasm antibodies of neutrophils in patients with cystic fibrosis with and without pseudomonas aeruginosa colonization. Pediatr Med Chir 2001;23:27-30.
26. van der Schaft DW, Toebes EA, Haseman JR, Mayo KH, Griffioen AW. Bactericidal/permeability-increasing protein inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 2000;96:176-81.
27. LaRosa CA, Rohrer MJ, Benoit SE, Rodino LJ, Barnard MR, Michelson AD. Human neutrophil cathepsin G is a potent platelet activator. J Vasc Surg 1994;19:306-18.
28. Halbwachs-Mecarelli L, Nusbaum P, Noel LH, et al. Antineutrophilic cytoplasmic antibodies directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1992;90:79-84.
29. Zhao MH, Liu N, Zhang YK, Wang HY. Antineutrophil cytoplasmic autoantibodies and their target antigens in Chinese patients with lupus nephritis. Nephrol Dial Transplant 1998;13:2821-4.
30. Roozendaal C, Van Milligen de Wit AW, et al. Antineutrophilic cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med 1998;105:393-9.